TKA731

an orally bioavailable, non-peptide NK1-receptor antagonist for treatment of painful diabetic neuropathy; in randomised, controlled trial, no other information available 8/2005

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Graf, Ana: 1 article (08/2006)
2.	Sindrup, Søren H: 1 article (08/2006)
3.	Sfikas, Nikolaos: 1 article (08/2006)

Related Diseases

1.	Pain (Aches) 08/01/2006 - "There was no significant difference between TKA731 and placebo in change in pain rating from baseline to study end neither for rating of total pain (mean -13.4 mm vs. -11.6 mm, p = 0.664) nor for change in ratings of different pain symptoms (touch- or pressure-evoked pain, pain paroxysms, steady burning or deep aching pain) (p = 0.169-0.834)."
2.	Diabetic Neuropathies (Diabetic Neuropathy) 08/01/2006 - "The aim of this multicenter, randomised, double-blind, placebo-controlled and parallel-group study was to test if the non-peptide NK(1)-receptor antagonist TKA731 would relieve painful diabetic polyneuropathy. " 08/01/2006 - "The NK1-receptor antagonist TKA731 in painful diabetic neuropathy: a randomised, controlled trial."